论文部分内容阅读
膀胱肿瘤作为最为常见泌尿系的恶性肿瘤,约占全部恶性肿瘤的3%,男性恶性肿瘤排名为第6位,女性为第10位[1],且其复发率高,有25%的患者会进展成为侵袭性膀胱癌[2],且其放化疗效果均不满意,最终约50%侵袭性膀胱癌转移危及生命[3],因此从膀胱癌的发生的分子机制上进行深入的研究,寻找同膀胱癌发生发展密切相关的分子,为治疗膀胱癌提供新的治疗选择或提高放化疗治疗效果的辅助治疗措施,对膀胱癌的治疗都有着重要的意义。
Bladder cancer is the most common malignancy of the urinary tract, accounting for about 3% of all malignancies, with the sixth most common cancer in men and the tenth most common in women [1], with a high recurrence rate of 25% Progress to become invasive bladder cancer [2], and its radiotherapy and chemotherapy are not satisfied, and eventually about 50% of invasive bladder cancer metastasis life-threatening [3], so from the molecular mechanism of bladder cancer in-depth study to find Bladder cancer is closely related to the development of molecules for the treatment of bladder cancer to provide new treatment options or to improve the effect of adjuvant chemotherapy and radiotherapy treatment of bladder cancer treatment are of great significance.